[
  {
    "ts": "2025-03-17T20:52:50+00:00",
    "headline": "Incyte stock dives after drug trial disappoints investors",
    "summary": "Incyte (INCY) shares are sinking after its third phase results for Povorcitinib, a drug for chronic skin disease, were less promising than those from earlier trials. Yahoo Finance Senior Reporter Anjalee Khemlani outlines the details on Market Domination. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finance.yahoo.com/video/incyte-stock-dives-drug-trial-205250038.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "7f7ba435-64b6-3576-bb5c-c42ee1de38bc",
      "content": {
        "id": "7f7ba435-64b6-3576-bb5c-c42ee1de38bc",
        "contentType": "VIDEO",
        "title": "Incyte stock dives after drug trial disappoints investors",
        "description": "<p>Incyte (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/INCY\">INCY</a>) shares are sinking after its third phase results for Povorcitinib, a drug for chronic skin disease, were less promising than those from earlier trials.</p>\n<p>Yahoo Finance Senior Reporter <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/author/anjalee-khemlani/\">Anjalee Khemlani</a> outlines the details on Market Domination.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more Market Domination <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-domination/\">here</a>.</p>",
        "summary": "Incyte (INCY) shares are sinking after its third phase results for Povorcitinib, a drug for chronic skin disease, were less promising than those from earlier trials. Yahoo Finance Senior Reporter Anjalee Khemlani outlines the details on Market Domination. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
        "pubDate": "2025-03-17T20:52:50Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-03/39055f10-036c-11f0-b9ef-7d2d960a24f4",
          "originalWidth": 5000,
          "originalHeight": 2815,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/x.4T.gUWODR89b1dTwrnHw--~B/aD0yODE1O3c9NTAwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-03/39055f10-036c-11f0-b9ef-7d2d960a24f4.cf.webp",
              "width": 5000,
              "height": 2815,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6nSUpJiGgVX_wkKUA0CKKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-03/39055f10-036c-11f0-b9ef-7d2d960a24f4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/incyte-stock-dives-drug-trial-205250038.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/incyte-stock-dives-drug-trial-205250038.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T20:32:07+00:00",
    "headline": "S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision",
    "summary": "The S&P 500 edged up 0.6% on Monday, March 17, after a report showed retail sales recovered in February but fell short of expectations.",
    "url": "https://www.investopedia.com/s-and-p-500-gains-and-losses-today-index-ticks-higher-ahead-of-this-weeks-fed-decision-11698250",
    "source": "Investopedia",
    "provider": "yfinance",
    "raw": {
      "id": "cffa41cc-4df7-3558-ba6d-373d5b80185d",
      "content": {
        "id": "cffa41cc-4df7-3558-ba6d-373d5b80185d",
        "contentType": "STORY",
        "title": "S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision",
        "description": "",
        "summary": "The S&P 500 edged up 0.6% on Monday, March 17, after a report showed retail sales recovered in February but fell short of expectations.",
        "pubDate": "2025-03-17T20:32:07Z",
        "displayTime": "2025-03-17T20:32:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/investopedia_245/1b3fb38f3ffaa99ef1053eae94d75020",
          "originalWidth": 5392,
          "originalHeight": 3595,
          "caption": "Michael M. Santiago/Getty Images",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/384s5xeyaTaIdV2RKp_fAg--~B/aD0zNTk1O3c9NTM5MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/investopedia_245/1b3fb38f3ffaa99ef1053eae94d75020.cf.webp",
              "width": 5392,
              "height": 3595,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/elTNJeqHRoergLFV1781.A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investopedia_245/1b3fb38f3ffaa99ef1053eae94d75020.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investopedia",
          "url": "https://www.investopedia.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investopedia.com/s-and-p-500-gains-and-losses-today-index-ticks-higher-ahead-of-this-weeks-fed-decision-11698250",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/p-500-gains-losses-today-203207051.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "INTC"
            },
            {
              "symbol": "INCY"
            },
            {
              "symbol": "AES"
            },
            {
              "symbol": "ENPH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T20:11:31+00:00",
    "headline": "Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'",
    "summary": "Incyte's skin disease treatment looks \"viable, but not competitive with biologics,\" an analyst said Monday as Incyte stock fell.",
    "url": "https://www.investors.com/news/technology/incyte-stock-hs-treatment-study/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "d4572b6f-f48c-3f53-ba65-2703d5995485",
      "content": {
        "id": "d4572b6f-f48c-3f53-ba65-2703d5995485",
        "contentType": "STORY",
        "title": "Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'",
        "description": "",
        "summary": "Incyte's skin disease treatment looks \"viable, but not competitive with biologics,\" an analyst said Monday as Incyte stock fell.",
        "pubDate": "2025-03-17T20:11:31Z",
        "displayTime": "2025-03-17T20:11:31Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d4572b6f-f48c-3f53-ba65-2703d5995485/incyte-loses-9-as-skin.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/9f00ed780f1af84c9dfaf3957093097a",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6X6vzuM23HDYflHOM_9Jw--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/9f00ed780f1af84c9dfaf3957093097a.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EBitEPZAf7N.1eCj4CCXYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/9f00ed780f1af84c9dfaf3957093097a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/incyte-stock-hs-treatment-study/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T18:09:24+00:00",
    "headline": "Oil pressures, Robinhood, Incyte: Market Minute",
    "summary": "Yahoo Finance host Julie Hyman is tracking some of the biggest stock stories in this Market Minute, including Red Sea tensions pressuring oil prices (CL=F, BZ=F), the launch of Robinhood Markets' (HOOD) prediction markets hub, and Incyte's (INCY) Phase 3 trial data on a skin condition treatment. Stay up to date on the latest market action, minute-by-minute, with&nbsp;Yahoo Finance's Market Minute.",
    "url": "https://finance.yahoo.com/video/oil-pressures-robinhood-incyte-market-180924513.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "31fccf8c-b3e2-3123-a6d8-740dbac46fa0",
      "content": {
        "id": "31fccf8c-b3e2-3123-a6d8-740dbac46fa0",
        "contentType": "VIDEO",
        "title": "Oil pressures, Robinhood, Incyte: Market Minute",
        "description": "<p>Yahoo Finance host <a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/author/julie-hyman/\">Julie Hyman</a> is tracking some of the biggest stock stories in this<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-minute/\"> Market Minute</a>, including Red Sea tensions pressuring oil prices (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/CL=F\">CL=F</a>, <a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/BZ=F\">BZ=F</a>), the launch of Robinhood Markets' (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/HOOD\">HOOD</a>) prediction markets hub, and Incyte's (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/INCY\">INCY</a>) Phase 3 trial data on a skin condition treatment.</p>\n<p>Stay up to date on the latest market action, minute-by-minute, with <a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-minute/\">Yahoo Finance's Market Minute.</a></p>",
        "summary": "Yahoo Finance host Julie Hyman is tracking some of the biggest stock stories in this Market Minute, including Red Sea tensions pressuring oil prices (CL=F, BZ=F), the launch of Robinhood Markets' (HOOD) prediction markets hub, and Incyte's (INCY) Phase 3 trial data on a skin condition treatment. Stay up to date on the latest market action, minute-by-minute, with&nbsp;Yahoo Finance's Market Minute.",
        "pubDate": "2025-03-17T18:09:24Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-03/ecf9a8d0-035a-11f0-bfdf-cd3d465a6637",
          "originalWidth": 2883,
          "originalHeight": 1623,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jCek0Cg_WCkfb9XYTnTaTg--~B/aD0xNjIzO3c9Mjg4MzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-03/ecf9a8d0-035a-11f0-bfdf-cd3d465a6637.cf.webp",
              "width": 2883,
              "height": 1623,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8hOp.i0CUK_gPjrDYdrTHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-03/ecf9a8d0-035a-11f0-bfdf-cd3d465a6637.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/oil-pressures-robinhood-incyte-market-180924513.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/oil-pressures-robinhood-incyte-market-180924513.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "BZ=F"
            },
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T17:59:34+00:00",
    "headline": "Top Midday Decliners",
    "summary": "Affirm (AFRM) retreated Monday after CNBC reported retailer Walmart (WMT) plans to select rival Swed",
    "url": "https://finance.yahoo.com/news/top-midday-decliners-175934951.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "5146d45e-2b29-3594-b49f-4dbab98b60de",
      "content": {
        "id": "5146d45e-2b29-3594-b49f-4dbab98b60de",
        "contentType": "STORY",
        "title": "Top Midday Decliners",
        "description": "",
        "summary": "Affirm (AFRM) retreated Monday after CNBC reported retailer Walmart (WMT) plans to select rival Swed",
        "pubDate": "2025-03-17T17:59:34Z",
        "displayTime": "2025-03-17T17:59:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-decliners-175934951.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-decliners-175934951.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "INCY"
            },
            {
              "symbol": "WMT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T17:52:06+00:00",
    "headline": "Why Incyte (INCY) Stock Is Nosediving",
    "summary": "Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment, which fell below Wall Street's expectations. According to the data, the drug was effective for less than half of the participants who took it in the trials.",
    "url": "https://finance.yahoo.com/news/why-incyte-incy-stock-nosediving-175206844.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "3332d575-4e83-3ba6-bb56-f244335ae25f",
      "content": {
        "id": "3332d575-4e83-3ba6-bb56-f244335ae25f",
        "contentType": "STORY",
        "title": "Why Incyte (INCY) Stock Is Nosediving",
        "description": "",
        "summary": "Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment, which fell below Wall Street's expectations. According to the data, the drug was effective for less than half of the participants who took it in the trials.",
        "pubDate": "2025-03-17T17:52:06Z",
        "displayTime": "2025-03-17T17:52:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "INCY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9ebFa.LFGXWDaOAygGvuNg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ojCguUNIH7INClq6_Rac1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/dd5ed23043756cdda4b65d5c228863e0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-incyte-incy-stock-nosediving-175206844.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-incyte-incy-stock-nosediving-175206844.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T17:11:05+00:00",
    "headline": "Incyte stock hit by 11% despite paediatric dermatology trials hitting target",
    "summary": "The US company’s two simultaneous trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.",
    "url": "https://www.clinicaltrialsarena.com/news/incyte-stock-hit-11-despite-paediatric-dermatology-trials-hitting-target/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "2d6ec572-c16e-3949-974b-89c5912b1b85",
      "content": {
        "id": "2d6ec572-c16e-3949-974b-89c5912b1b85",
        "contentType": "STORY",
        "title": "Incyte stock hit by 11% despite paediatric dermatology trials hitting target",
        "description": "",
        "summary": "The US company’s two simultaneous trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.",
        "pubDate": "2025-03-17T17:11:05Z",
        "displayTime": "2025-03-17T17:11:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/288936666ef480b57e4f2956406d151a",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FndANs.Zdt70p1IMaFenlg--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/288936666ef480b57e4f2956406d151a.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6u_i8dglO9D5FsvTFgyBKA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/288936666ef480b57e4f2956406d151a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/incyte-stock-hit-11-despite-paediatric-dermatology-trials-hitting-target/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-stock-hit-11-despite-171105233.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            },
            {
              "symbol": "GLDAF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T16:00:54+00:00",
    "headline": "Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results",
    "summary": "Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.",
    "url": "https://www.investopedia.com/incyte-leads-s-and-p-500-decliners-on-skin-condition-drug-trial-results-11698133",
    "source": "Investopedia",
    "provider": "yfinance",
    "raw": {
      "id": "fccdb2b4-c834-3503-a833-ffc69c4415a8",
      "content": {
        "id": "fccdb2b4-c834-3503-a833-ffc69c4415a8",
        "contentType": "STORY",
        "title": "Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results",
        "description": "",
        "summary": "Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.",
        "pubDate": "2025-03-17T16:00:54Z",
        "displayTime": "2025-03-17T16:00:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/investopedia_245/719a161872f1b45b18931a38663b00ee",
          "originalWidth": 5000,
          "originalHeight": 3333,
          "caption": "Piotr Swat / SOPA Images / LightRocket / Getty Images",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9Fh7l0Say_Shkfi.QI37_A--~B/aD0zMzMzO3c9NTAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/investopedia_245/719a161872f1b45b18931a38663b00ee.cf.webp",
              "width": 5000,
              "height": 3333,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wR1G9pxaWkKDhApEi_MT5Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investopedia_245/719a161872f1b45b18931a38663b00ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investopedia",
          "url": "https://www.investopedia.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investopedia.com/incyte-leads-s-and-p-500-decliners-on-skin-condition-drug-trial-results-11698133",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-leads-p-500-decliners-160054190.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T16:00:36+00:00",
    "headline": "Top Stock Movers Now: Intel, Netflix, Incyte, and More",
    "summary": "U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.",
    "url": "https://www.investopedia.com/top-stock-movers-now-intel-netflix-incyte-and-more-11698185",
    "source": "Investopedia",
    "provider": "yfinance",
    "raw": {
      "id": "85e0a3dc-9f61-30e9-935a-3206c80f51e9",
      "content": {
        "id": "85e0a3dc-9f61-30e9-935a-3206c80f51e9",
        "contentType": "STORY",
        "title": "Top Stock Movers Now: Intel, Netflix, Incyte, and More",
        "description": "",
        "summary": "U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.",
        "pubDate": "2025-03-17T16:00:36Z",
        "displayTime": "2025-03-17T16:00:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/investopedia_245/a67d680e9953063509fe532eac0bdadc",
          "originalWidth": 6000,
          "originalHeight": 4000,
          "caption": "Eric Alonso / Getty Images",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YpReRSX8oheU1_ridEKcEA--~B/aD00MDAwO3c9NjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/investopedia_245/a67d680e9953063509fe532eac0bdadc.cf.webp",
              "width": 6000,
              "height": 4000,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A.IXhYG50l79S.d.VUpvVw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investopedia_245/a67d680e9953063509fe532eac0bdadc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investopedia",
          "url": "https://www.investopedia.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investopedia.com/top-stock-movers-now-intel-netflix-incyte-and-more-11698185",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-stock-movers-now-intel-160036811.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            },
            {
              "symbol": "INTC"
            },
            {
              "symbol": "NFLX"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T13:53:31+00:00",
    "headline": "Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls",
    "summary": "On Monday, Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin condition characterized by painful, recurrent boil-like lumps, often in areas where skin rubs together like the armpits and groin, that can lead",
    "url": "https://finance.yahoo.com/news/incytes-treatment-chronic-skin-disease-135331760.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "3d869157-0853-3027-a3c9-aa04c3cac94d",
      "content": {
        "id": "3d869157-0853-3027-a3c9-aa04c3cac94d",
        "contentType": "STORY",
        "title": "Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls",
        "description": "",
        "summary": "On Monday, Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin condition characterized by painful, recurrent boil-like lumps, often in areas where skin rubs together like the armpits and groin, that can lead",
        "pubDate": "2025-03-17T13:53:31Z",
        "displayTime": "2025-03-17T13:53:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/796b5bc53438b1d86cb7d6249d58572b",
          "originalWidth": 983,
          "originalHeight": 553,
          "caption": "Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1gMUKT2zNJCmBuId_r3o2g--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/796b5bc53438b1d86cb7d6249d58572b.cf.webp",
              "width": 983,
              "height": 553,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xMya9KQwDwNIa1zYXwq2HA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/796b5bc53438b1d86cb7d6249d58572b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incytes-treatment-chronic-skin-disease-135331760.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incytes-treatment-chronic-skin-disease-135331760.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-03-17T11:00:00+00:00",
    "headline": "Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa",
    "summary": "WILMINGTON, Del., March 17, 2025--Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis Suppurativa",
    "url": "https://finance.yahoo.com/news/incyte-announces-positive-topline-results-110000574.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "0f879359-1937-356d-b6a2-094942abbcd3",
      "content": {
        "id": "0f879359-1937-356d-b6a2-094942abbcd3",
        "contentType": "STORY",
        "title": "Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa",
        "description": "",
        "summary": "WILMINGTON, Del., March 17, 2025--Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis Suppurativa",
        "pubDate": "2025-03-17T11:00:00Z",
        "displayTime": "2025-03-17T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/53f86003d8c6fef478d3bd4c42d2b418",
          "originalWidth": 480,
          "originalHeight": 349,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5TPZbz4hgL3juFzBAK9uOA--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/53f86003d8c6fef478d3bd4c42d2b418.cf.webp",
              "width": 480,
              "height": 349,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eVTnHtxRLeOER65npRco.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/53f86003d8c6fef478d3bd4c42d2b418.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/incyte-announces-positive-topline-results-110000574.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/incyte-announces-positive-topline-results-110000574.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INCY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]